# Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-dk-21-012-support-for-small-business-innovation-research-sbir-to/  
Official notice: https://www.grants.gov/search-results-detail/333668

> National Institutes of Health offered grants to small businesses. It expected to make $3.0 million in total. Applications closed on October 7, 2022.

| Field | Value |
|---|---|
| Opportunity number | RFA-DK-21-012 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | October 7, 2022 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | $3.0 million |
| Cost sharing | not required |
| Assistance Listings | 93.847 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.

## Questions people ask

### Is RFA-DK-21-012 still open?

No. It closed on October 7, 2022.

### Who can apply for Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)?

Closed October 7, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $3.0 million in total.

### Who has been funded under RFA-DK-21-012?

NIH RePORTER lists 2 projects funded under RFA-DK-21-012 in fiscal 2023, at 2 institutions. The most were at Immunoshield Therapeutics Inc., Stembiosys, Inc.

### Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.